The role of Fc-FcγR interactions in IgG-mediated microbial neutralization

Journal of Experimental Medicine

Volumn 212, Issue 9, 2015, Pages 1361-1369

  Bournazos, Stylianos ^a   DiLillo, David J ^a   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ANTIGEN BINDING; EFFECTOR CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STREPTOCOCCUS PNEUMONIA; ANIMAL; ANTIGEN ANTIBODY REACTION; GENE EXPRESSION REGULATION; IMMUNOLOGY; INFECTION; PATHOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGEN-ANTIBODY REACTIONS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN G; INFECTION; RECEPTORS, IGG;

EID: 84956963019     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20151267     Document Type: Review

References (72)

1. Abboud, N., S.K. Chow, C. Saylor, A. Janda, J.V. Ravetch, M.D. Scharff, and A. Casadevall. 2010. A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J. Exp. Med. 207:2395-2405. http://dx.doi.org/10.1084/jem.20100995
2. Ahmed, A.A., J. Giddens, A. Pincetic, J.V. Lomino, J.V. Ravetch, L.X. Wang, and P.J. Bjorkman. 2014. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J. Mol. Biol. 426:3166-3179. http://dx.doi.org/10.1016/j.jmb.2014.07.006
3. Anthony, R.M., and J.V. Ravetch. 2010. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J. Clin. Immunol. 30:S9-S14. http://dx.doi.org/10.1007/s10875-010-9405-6
4. Anthony, R.M., F. Wermeling, and J.V. Ravetch. 2012. Novel roles for the IgG Fc glycan. Ann. N. Y. Acad. Sci. 1253:170-180. http://dx.doi.org/10.1111/j.1749-6632.2011.06305.x
5. Balazs, A.B., J. Chen, C.M. Hong, D.S. Rao, L. Yang, and D. Baltimore. 2012. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 481:81-84. http://dx.doi.org/10.1038/nature10660
6. Barouch, D.H., J.B. Whitney, B. Moldt, F. Klein, T.Y. Oliveira, J. Liu, K.E. Stephenson, H.W. Chang, K. Shekhar, S. Gupta, et al. 2013. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 503:224-228.
7. Behring, E. 1890. Untersuchungen über das Zustandekommen der Diphtherie-Immunität bei Thieren. Dtsch. Med. Wochenschr. 16:1145-1148. http://dx.doi.org/10.1055/s-0029-1207609
8. Behring, E., and S. Kitasato. 1890. Ueber das Zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch. Med. Wochenschr. 16:1113-1114. http://dx.doi.org/10.1055/s-0029-1207589
9. Bournazos, S., S.P. Hart, L.H. Chamberlain, M.J. Glennie, and I. Dransfield. 2009a. Association of FcγRIIa (CD32a) with lipid rafts regulates ligand binding activity. J. Immunol. 182:8026-8036. http://dx.doi.org/10 .4049/jimmunol.0900107
10. Bournazos, S., J.M. Woof, S.P. Hart, and I. Dransfield. 2009b. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin. Exp. Immunol. 157:244-254. http://dx.doi.org/10.1111/j.1365-2249.2009.03980.x
11. Bournazos, S., S.K. Chow, N. Abboud, A. Casadevall, and J.V. Ravetch. 2014a. Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J. Clin. Invest. 124:725-729. http://dx.doi.org/10.1172/JCI72676
12. Bournazos, S., D.J. DiLillo, and J.V. Ravetch. 2014b. Humanized mice to study FcγR function. Curr. Top. Microbiol. Immunol. 382:237-248.
13. Bournazos, S., F. Klein, J. Pietzsch, M.S. Seaman, M.C. Nussenzweig, and J.V. Ravetch. 2014c. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 158:1243-1253. http://dx.doi.org/10.1016/j.cell.2014.08.023
14. Burton, D.R., R. Ahmed, D.H. Barouch, S.T. Butera, S. Crotty, A. Godzik, D.E. Kaufmann, M.J. McElrath, M.C. Nussenzweig, B. Pulendran, et al. 2012. A blueprint for HIV vaccine discovery. Cell Host Microbe. 12:396-407. http://dx.doi.org/10.1016/j.chom.2012.09.008
15. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood. 99:754-758. http://dx.doi.org/10.1182/blood.V99.3.754
16. Caskey, M., F. Klein, J.C. Lorenzi, M.S. Seaman, A.P. West Jr., N. Buckley, G. Kremer, L. Nogueira, M. Braunschweig, J.F. Scheid, et al. 2015. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 522:487-491. http://dx.doi.org/10.1038/nature14411
17. Chan, A.C., and P.J. Carter. 2010. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10:301-316. http://dx.doi .org/10.1038/nri2761
18. Clynes, R.A., T.L. Towers, L.G. Presta, and J.V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6:443-446. http://dx.doi.org/10.1038/74704
19. Corti, D., J. Voss, S.J. Gamblin, G. Codoni, A. Macagno, D. Jarrossay, S.G. Vachieri, D. Pinna, A. Minola, F. Vanzetta, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 333:850-856. http://dx.doi.org/10.1126/science.1205669
20. DiLillo, D.J., and J.V. Ravetch. 2015. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell. 161:1035-1045. http://dx.doi .org/10.1016/j.cell.2015.04.016
21. DiLillo, D.J., G.S. Tan, P. Palese, and J.V. Ravetch. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat. Med. 20:143-151. http://dx.doi.org/10.1038/nm.3443
22. Ekiert, D.C., G. Bhabha, M.A. Elsliger, R.H. Friesen, M. Jongeneelen, M. Throsby, J. Goudsmit, and I.A. Wilson. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science. 324:246-251. http://dx.doi.org/10.1126/science.1171491
23. El Bakkouri, K., F. Descamps, M. De Filette, A. Smet, E. Festjens, A. Birkett, N. Van Rooijen, S. Verbeek, W. Fiers, and X. Saelens. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186:1022-1031. http://dx.doi.org/10.4049/jimmunol.0902147
24. Fiebiger, B.M., J. Maamary, A. Pincetic, and J.V. Ravetch. 2015. Protection in antibody-and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc. Natl. Acad. Sci. USA. 112: E2385-E2394. http://dx.doi.org/10.1073/pnas.1505292112
25. Floto, R.A., M.R. Clatworthy, K.R. Heilbronn, D.R. Rosner, P.A. MacAry, A. Rankin, P.J. Lehner, W.H. Ouwehand, J.M. Allen, N.A. Watkins, and K.G. Smith. 2005. Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafts. Nat. Med. 11:1056-1058. http://dx.doi.org/10.1038/nm1288
26. Forthal, D.N., G. Landucci, J. Bream, L.P. Jacobson, T.B. Phan, and B. Montoya. 2007. FcγRIIa genotype predicts progression of HIV infection. J. Immunol. 179:7916-7923. http://dx.doi.org/10.4049/jimmunol .179.11.7916
27. Gaschen, B., J. Taylor, K. Yusim, B. Foley, F. Gao, D. Lang, V. Novitsky, B. Haynes, B.H. Hahn, T. Bhattacharya, and B. Korber. 2002. Diversity considerations in HIV-1 vaccine selection. Science. 296:2354-2360. http://dx.doi.org/10.1126/science.1070441
28. Goede, V., K. Fischer, R. Busch, A. Engelke, B. Eichhorst, C.M. Wendtner, T. Chagorova, J. de la Serna, M.S. Dilhuydy, T. Illmer, et al. 2014. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370:1101-1110. http://dx.doi.org/10.1056/NEJMoa1313984
29. Gogtay, N., U. Thatte, N. Kshirsagar, B. Leav, D. Molrine, P. Cheslock, S.V. Kapre, and P.S. Kulkarni. SII RMab author group. 2012. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine. 30:7315-7320. http://dx.doi.org/10.1016/j.vaccine.2012.09.027
30. Halper-Stromberg, A., C.L. Lu, F. Klein, J.A. Horwitz, S. Bournazos, L. Nogueira, T.R. Eisenreich, C. Liu, A. Gazumyan, U. Schaefer, et al. 2014. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 158:989-999. http://dx.doi.org/10.1016/j.cell.2014.07.043
31. Hessell, A.J., L. Hangartner, M. Hunter, C.E. Havenith, F.J. Beurskens, J.M. Bakker, C.M. Lanigan, G. Landucci, D.N. Forthal, P.W. Parren, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 449:101-104. http://dx.doi .org/10.1038/nature06106
32. Hiatt, A., N. Bohorova, O. Bohorov, C. Goodman, D. Kim, M.H. Pauly, J. Velasco, K.J. Whaley, P.A. Piedra, B.E. Gilbert, and L. Zeitlin. 2014. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc. Natl. Acad. Sci. USA. 111:5992-5997. http://dx.doi.org/10.1073/pnas.1402458111
33. Horwitz, J.A., A. Halper-Stromberg, H. Mouquet, A.D. Gitlin, A. Tretiakova, T.R. Eisenreich, M. Malbec, S. Gravemann, E. Billerbeck, M. Dorner, et al. 2013. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl. Acad. Sci. USA. 110:16538-16543. http://dx.doi.org/10.1073/pnas.1315295110
34. Huber, V.C., J.M. Lynch, D.J. Bucher, J. Le, and D.W. Metzger. 2001. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 166:7381-7388. http://dx.doi.org/10.4049/jimmunol.166.12.7381
35. Klein, F., A. Halper-Stromberg, J.A. Horwitz, H. Gruell, J.F. Scheid, S. Bournazos, H. Mouquet, L.A. Spatz, R. Diskin, A. Abadir, et al. 2012. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 492:118-122. http://dx.doi.org/10.1038/nature11604
36. Klein, F., H. Mouquet, P. Dosenovic, J.F. Scheid, L. Scharf, and M.C. Nussenzweig. 2013. Antibodies in HIV-1 vaccine development and therapy. Science. 341: 1199-1204. http://dx.doi.org/10.1126/science.1241144
37. Klein, J.S., and P.J. Bjorkman. 2010. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 6:e1000908. http://dx.doi.org/10.1371/journal.ppat.1000908
38. Knossow, M., M. Gaudier, A. Douglas, B. Barrère, T. Bizebard, C. Barbey, B. Gigant, and J.J. Skehel. 2002. Mechanism of neutralization of influenza virus infectivity by antibodies. Virology. 302:294-298. http://dx.doi.org/10.1006/viro.2002.1625
39. Korber, B., B. Gaschen, K. Yusim, R. Thakallapally, C. Kesmir, and V. Detours. 2001. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58:19-42. http://dx.doi.org/10.1093/bmb/58.1.19
40. Laursen, N.S., and I.A. Wilson. 2013. Broadly neutralizing antibodies against influenza viruses. Antiviral Res. 98:476-483. http://dx.doi.org/10.1016/j.antiviral.2013.03.021
41. Lee, Y.N., Y.T. Lee, M.C. Kim, H.S. Hwang, J.S. Lee, K.H. Kim, and S.M. Kang. 2014. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination. Immunology. 143:300-309. http://dx.doi.org/10.1111/imm.12310
42. Li, F., and J.V. Ravetch. 2011. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 333:1030-1034. http://dx.doi.org/10.1126/science.1206954
43. Lowy, I., D.C. Molrine, B.A. Leav, B.M. Blair, R. Baxter, D.N. Gerding, G. Nichol, W.D. Thomas Jr., M. Leney, S. Sloan, et al. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205. http://dx.doi.org/10.1056/NEJMoa0907635
44. Lux, A., X. Yu, C.N. Scanlan, and F. Nimmerjahn. 2013. Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J. Immunol. 190:4315-4323. http://dx.doi.org/10.4049/jimmunol.1200501
45. Mascola, J.R., G. Stiegler, T.C. VanCott, H. Katinger, C.B. Carpenter, C.E. Hanson, H. Beary, D. Hayes, S.S. Frankel, D.L. Birx, and M.G. Lewis. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210. http://dx.doi.org/10.1038/72318
46. Migone, T.S., G.M. Subramanian, J. Zhong, L.M. Healey, A. Corey, M. Devalaraja, L. Lo, S. Ullrich, J. Zimmerman, A. Chen, et al. 2009. Raxibacumab for the treatment of inhalational anthrax. N. Engl. J. Med. 361:135-144. http://dx.doi.org/10.1056/NEJMoa0810603
47. Moore, P.L., E.S. Gray, C.K. Wibmer, J.N. Bhiman, M. Nonyane, D.J. Sheward, T. Hermanus, S. Bajimaya, N.L. Tumba, M.R. Abrahams, et al. 2012. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18:1688-1692. http://dx .doi.org/10.1038/nm.2985
48. Musolino, A., N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, D. Laccabue, A. Zerbini, R. Camisa, G. Bisagni, et al. 2008. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumabbased therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26:1789-1796. http://dx.doi.org/10.1200/JCO.2007.14.8957
49. Natsume, A., R. Niwa, and M. Satoh. 2009. Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug Des. Devel. Ther. 3:7-16.
50. Nimmerjahn, F., and J.V. Ravetch. 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 310:1510-1512. http://dx.doi.org/10.1126/science.1118948
51. Nimmerjahn, F., and J.V. Ravetch. 2006. Fcγ receptors: old friends and new family members. Immunity. 24:19-28. http://dx.doi.org/10.1016/j.immuni.2005.11.010
52. Nimmerjahn, F., and J.V. Ravetch. 2007. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19:239-245. http://dx.doi.org/10.1016/j.coi .2007.01.005
53. Nimmerjahn, F., and J.V. Ravetch. 2008. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8:34-47. http://dx.doi.org/10.1038/nri2206
54. Page, D.B., M.A. Postow, M.K. Callahan, J.P. Allison, and J.D. Wolchok. 2014. Immune modulation in cancer with antibodies. Annu. Rev. Med. 65:185-202. http://dx.doi.org/10.1146/annurev-med-092012-112807
55. Pietzsch, J., H. Gruell, S. Bournazos, B.M. Donovan, F. Klein, R. Diskin, M.S. Seaman, P.J. Bjorkman, J.V. Ravetch, A. Ploss, and M.C. Nussenzweig. 2012. A mouse model for HIV-1 entry. Proc. Natl. Acad. Sci. USA. 109:15859-15864. http://dx.doi.org/10.1073/pnas.1213409109
56. Pincetic, A., S. Bournazos, D.J. DiLillo, J. Maamary, T.T. Wang, R. Dahan, B.M. Fiebiger, and J.V. Ravetch. 2014. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15:707-716. http://dx.doi.org/10.1038/ni.2939
57. Qiu, W.Q., D. de Bruin, B.H. Brownstein, R. Pearse, and J.V. Ravetch. 1990. Organization of the human and mouse low-affinity Fc gamma R genes: duplication and recombination. Science. 248:732-735. http://dx.doi.org/10.1126/science.2139735
58. Qiu, X., J. Audet, G. Wong, L. Fernando, A. Bello, S. Pillet, J.B. Alimonti, and G.P. Kobinger. 2013. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci. Rep. 3:3365. http://dx.doi.org/10.1038/srep03365
59. Sanford, J.E., D.M. Lupan, A.M. Schlageter, and T.R. Kozel. 1990. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect. Immun. 58:1919-1923.
60. Schlageter, A.M., and T.R. Kozel. 1990. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect. Immun. 58:1914-1918.
61. Schmitz, N., R.R. Beerli, M. Bauer, A. Jegerlehner, K. Dietmeier, M. Maudrich, P. Pumpens, P. Saudan, and M.F. Bachmann. 2012. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur. J. Immunol. 42:863-869. http://dx.doi.org/10.1002/eji.201041225
62. Schwab, I., and F. Nimmerjahn. 2013. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13:176-189. http://dx.doi.org/10.1038/nri3401
63. Shingai, M., Y. Nishimura, F. Klein, H. Mouquet, O.K. Donau, R. Plishka, A. Buckler-White, M. Seaman, M. Piatak Jr., J.D. Lifson, et al. 2013. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature. 503:277-280.
64. Simek, M.D., W. Rida, F.H. Priddy, P. Pung, E. Carrow, D.S. Laufer, J.K. Lehrman, M. Boaz, T. Tarragona-Fiol, G. Miiro, et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348. http://dx.doi.org/10.1128/JVI.00110-09
65. Smith, P., D.J. DiLillo, S. Bournazos, F. Li, and J.V. Ravetch. 2012. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA. 109:6181-6186. http://dx.doi.org/10.1073/pnas.1203954109
66. Sondermann, P., A. Pincetic, J. Maamary, K. Lammens, and J.V. Ravetch. 2013. General mechanism for modulating immunoglobulin effector function. Proc. Natl. Acad. Sci. USA. 110:9868-9872. http://dx.doi.org/10.1073/pnas.1307864110
67. Tan, G.S., F. Krammer, D. Eggink, A. Kongchanagul, T.M. Moran, and P. Palese. 2012. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J. Virol. 86:6179-6188. http://dx.doi.org/10.1128/JVI.00469-12
68. Varshney, A.K., X. Wang, J.L. Aguilar, M.D. Scharff, and B.C. Fries. 2014. Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice. MBio. 5:e01007-e01014. http://dx.doi.org/10.1128/mBio.01007-14
69. Weber, S., H. Tian, N. van Rooijen, and L.A. Pirofski. 2012. A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fcγ receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice. Infect. Immun. 80:1314-1322. http://dx.doi.org/10.1128/IAI.06081-11
70. Weng, W.K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21:3940-3947. http://dx.doi.org/10.1200/JCO.2003.05.013
71. Wiley, D.C., I.A. Wilson, and J.J. Skehel. 1981. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature. 289:373-378. http://dx.doi.org/10.1038/289373a0
72. Yoshihara, S., S. Kusuda, H. Mochizuki, K. Okada, S. Nishima, and E.A. Simões. C-CREW Investigators. 2013. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants. Pediatrics. 132:811-818. http://dx.doi.org/10.1542/peds.2013-0982